Skip to main content

Table 1 Patient characteristics

From: HPV positive, wild type TP53, and p16 overexpression correlate with the absence of residual tumors after chemoradiotherapy in anal squamous cell carcinoma

Characteristics

N

%

HPV Positive

N (%)

HPV Negative

N (%)

p-value

Age

    

0.361

 < 65 years old

44

56.4%

   

 ≥ 65 years old

34

43.6%

35 (59.3)

9 (47.4)

 

Gender

  

24 (40.7)

10 (52.6)

0.004

 Female

64

82.1

   

 Male

14

17.9

53 (89.8)

11 (57.9)

 

Degree of Cellular Differentiation

  

6 (10.2)

8 (42.1)

0.351

 G I

6

7.7

   

 G II

58

74.4

6 (10.2)

0 (0)

 

 G III

11

14.1

42 (71.2)

16 (84.2)

 

 G IV

3

3.8

8 (13.6)

3 (15.8)

 

Clinical Stage (UICC)

  

3 (5.1)

0 (0)

0.031

 I

5

6.4

   

 II

47

60.3

5 (8.5)

0 (0)

 

 IIIA

16

20.5

39 (66.1)

8 (42.1)

 

 IIIB

10

12.8

8 (13.6)

8 (42.1)

 

N Stage

  

7 (11.9)

3 (15.8)

0.354

 Negative

60

76.9

   

 Positive

18

23.1

47 (79.7)

13 (68.4)

 

T Stage

  

12 (20.3)

6 (31.6)

0,012

 T1 (≤ 2 cm)

6

7.7

   

 T2 (> 2 and ≤5 cm)

30

38.5

6 (10.2)

0 (0)

 

 T3 (>  5 cm)

30

38.5

27 (45.8)

3 (15.8)

 

 T4 (tumour invading adjacent organ)

12

15.4

20 (33.9)

10 (52.6)

 

HPV

  

6 (10.2)

6 (31.6)

NA

 16

49

62.8

   

 18

10

12.8

49 (62.8)

0 (0)

 

 Negative

19

24.4

10 (12.8)

0 (0)

 

HIV

  

19 (24.4)

0 (0)

1.000

Positive

19

24.4

   

Negative

59

75.6

14 (23.7)

5 (26.3)

 

P16

  

45 (76.3)

14 (73.7)

< 0.001

 Positive

57

73.1

   

 Negative

19

24.4

57 (96.6)

0 (0)

 

Borderline

2

2.6

0 (0)

19 (100.0)

 

Clinical response at 6 months

  

2 (3.4)

0 (0)

< 0.001

 Yes

47

60.3

   

 No

31

39.7

47 (79.7)

0 (0)

 

TP53

  

12 (20.3)

19 (100.0)

< 0.001

 Mutated

21

26.9

   

 Wild type

57

73.1

2 (3.4)

19 (100.0)

 

Total

78

100.0

57 (96.6)

0 (0)

 
  1. NA = Not available
  2. Statistically significant p-values are shown in bold